|
| |
 |
| CASE REPORT |
|
| Year : 2012 | Volume
: 16
| Issue : 1 | Page : 141-143 |
|
Hypertriglyceridemia-induced recurrent acute pancreatitis: A case-based review
Sunil K Kota1, Siva K Kota2, Sruti Jammula3, S. V. S. Krishna1, Kirtikumar D Modi1
1 Department of Endocrinology, Medwin Hospital, Hyderabad, Andhra Pradesh, India
2 Department of Anesthesia, Central Security Hospital, Riyadh, Saudi Arabia
3 Department of Pharmaceutics, Roland Institute of Pharmaceutical Sciences, Berhampur, Orissa, India
| Date of Web Publication | 26-Dec-2011 |
Correspondence Address:
Sunil K Kota
Department of Endocrinology, Medwin Hospitals, Chiragh Ali Lane, Nampally, Hyderabad - 500001, Andhra Pradesh
India
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/2230-8210.91211
 Abstract | | |
Hypertriglyceridemia is a rare, but well-known cause of acute pancreatitis. A serum triglyceride level of more than 1000 to 2000 mg / dl is the identifiable risk factor. It typically presents as an episode of acute pancreatitis or recurrent acute pancreatitis. The clinical course and routine management of Hypertriglyceridemia-induced pancreatitis is similar to other causes. A thorough family history is important, as is the identification of secondary causes of hypertriglyceridemia. The mainstay of therapy includes dietary restriction of fatty meal and fibric acid derivatives. We hereby report the case of a 37-year-old lady with a family history of dyslipidemia presenting with recurrent episodes of acute pancreatitis. We also review the literature for pathogenesis and management of hyperlipidemia. Keywords: Acute pancreatitis, fibric acid derivatives, hypertriglyceridemia, hyperlipidemia
How to cite this article:
Kota SK, Kota SK, Jammula S, Krishna S, Modi KD. Hypertriglyceridemia-induced recurrent acute pancreatitis: A case-based review. Indian J Endocr Metab 2012;16:141-3 |
How to cite this URL:
Kota SK, Kota SK, Jammula S, Krishna S, Modi KD. Hypertriglyceridemia-induced recurrent acute pancreatitis: A case-based review. Indian J Endocr Metab [serial online] 2012 [cited 2021 Mar 9];16:141-3. Available from: https://www.ijem.in/text.asp?2012/16/1/141/91211 |
| Introduction | |  |
Acute pancreatitis is a common condition with various possible etiologies, gall stones and alcohol being the most common. [1] Metabolic, structural, and iatrogenic causes account for 20 - 25% of the cases. [2] Hyperlipidemia in the form of hypertriglyceridemia or chylomicronemia, although less frequent, is one of the well-accepted underlying causes of acute pancreatitis in 7% of the cases - the most common after gall stones and alcohol. [3] Typically hypertriglyceridemia-induced pancreatitis occurs in a patient with a pre-existing lipid abnormality, along with the presence of a secondary precipitating factor (e.g., poorly controlled diabetes, alcohol or medication). The triglyceride levels of more than 1000 to 2000 mg / dl in patients with type I, III, IV, and V hyperlipoproteinemia (Friedrickson's classification) is the identifiable risk factor. [4] Genetic factors determine over 60% of the variability in serum lipids. [5] The secondary causes of hypertriglyceridemia have to be ruled out. Most patients can be effectively treated with the existing drug therapy. Heparin and insulin have a role to play in the treatment. [6] Other novel modalities include plasma exchange and lipid aphaeresis. [7] Here we report a lady presenting with recurrent pancreatitis, with features of hyperlipidemia, and review the literature for pathogenesis and management of hyperlipidemia.
| Case Report | | |
A 37-year-old female presented with a chief complaint of epigastric pain for three days. The pain was continuous, radiating to the back, and associated with two episodes of bilious vomiting. She was not receiving hypolipidemic agents for last three months against physician's advice. Four years back she presented with similar complaints and was diagnosed as having acute pancreatitis with type 2 diabetes, hypertension, and combined dyslipidemia. Treatment was started with insulin, telmisartan, atrorvastatin, fenofibrate, and a low-fat diet. In between, after stopping treatment on her own, she ended up with two episodes of acute pancreatitis. Laboratory parameters during the previous three presentations are depicted in [Table 1]. Two of her elder brothers died at the age of 40 to 45 years, because of coronary artery disease and combined dyslipidemias. One younger sister was also a known case of combined dyslipidemia, on treatment. | Table 1: Laboratory parameters of the patient during the previous three presentations with acute pancreatitis
Click here to view |
On examination, her pulse rate was 120 / minute, blood pressure 150 / 100 mm Hg, respiratory rate 26 / minute, and temperature 101.4 0 F. She was somnolent and dehydrated. There was a markedly tender and rigid epigastrium, with diminished bowel sounds and hepatosplenomegaly. She had arcussenilis and lipemiaretinalis, but no eruptive xanthoma. Initial laboratory findings were a total leukocyte count of 16000 / cmm with 86% neutrophils, platelets 220000 / cmm, and c-reactive protein 17.2 gm / dl. Serum electrolytes, calcium, liver, and renal function tests, and lactate dehydrogenase and coagulation tests were normal. Serum was lipemic. Other investigations were as follows, total cholesterol 741 mg / dl, Low-density lipoprotein (LDL) cholesterol 249 mg / 74 mg / dl, very-low-density lipoprotein (VLDL) cholesterol 416 mg / dl, and triglycerides 2080 mg / dl. Fasting blood sugar (FBS) was 174 mg / dl and post-lunch blood sugar (PLBS) was 286 mg / dl. Ultrasonography of the abdomen showed a grade 1 fatty liver, hepetosplenomegaly with a bulky body, and the tail of the pancreas. Enlarged and edematous pancreas with smooth, ill-defined margins, a non-visualized pancreatic duct, and peripancreatic fat stranding were seen in a computed tomogram of the abdomen [Figure 1]. The patient was conservatively managed with intravenous fluids and narcotics for pain control. On the basis of high triglycerides, cholesterol, and VLDL cholesterol, a diagnosis of type IIb hyperlipoproteinemia (Familial Combined Hyperlipidemia / FCHL) was established. Treatment with fenofibrate 160 mg, atorvastatin 20 mg, and omega-3 fatty acids 2 g, twice daily, with antioxidants was started. After stabilization endoscopic retrograde cholangiopancreatography found no anatomic abnormality. The patient was discharged with insulin, antihypertensive, and hypolipidemic agents. | Figure 1: CT abdomen showing enlarged and edematous pancreas with smooth, ill-defined margins, non-visualized pancreatic duct, and peripancreatic fat stranding
Click here to view |
| Discussion | | |
The association between acute pancreatitis and hyperlipidemia is well known, both as a precipitant and as an epiphenomenon. [8] The coexistent medical conditions such as diabetes should prompt further workup. [9] Hypertriglyceridemia can be primary in less than 5% of the cases, due to genetic causes and more often secondary to other causes like diabetes, obesity, pregnancy, excess carbohydrate intake, hypothyroidism, alcohol, hepatitis, sepsis, renal failure, and drugs like estrogen, glucocorticoids, β blocker, bile acid binding resins, thiazide, tamoxifen cyclosporine protease inhibitors, and isotretinoin.[10]
In our patient, the presence of a family history of dyslipidemia, with laboratory values of high cholesterol, LDL cholesterol, VLDL cholesterol, and triglycerides, led us to the diagnosis of type IIb hyperlipoproteinemia.
Chylomicrons are triglyceride-rich lipoprotein particles. They are present in the circulation when triglycerides are > 10 mmol / l (900 mg / dl). These are large enough to occlude the pancreatic capillaries, leading to ischemia and subsequent acinar structural alteration, as also a release of pancreatic lipase. Enhanced lipolysis leads to an increased concentration of free fatty acids, which results in the release of inflammatory mediators and free radicals culminating in inflammation, edema, and necrosis. [11] Our patient had a total of four episodes of pancreatitis (each time triglycerides were > 900 mg / dl) after stopping the hyolipidemic agent each time.
Chylomicrons are the product of dietary fat absorption. Therefore, abstinence from eating after pancreatitis may allow rapid metabolism of the triglyceride-rich chylomicrons. [2] Other non-pharmacological measures include weight reduction, reduced calories, fat, and refined carbohydrate intake. Our patient was advised to restrict fat to 10 - 15% of total energy intake (about 15 - 20 gm / day) with reduction in saturated fats and unsaturated and trans fats. [12]
Fibrates are the mainstay of therapy, they reduce plasma triglyceride levels by up to 50% and raise the high-density lipoprotein (HDL) cholesterol by 20%. [13] They modulate peroxisome proliferator activated receptors-α (PPAR-α) in the liver, with decreased hepatic secretion of VLDL and increased lipolysis of the plasma triglyceride.[14] They also reduce small dense LDL particles and increase HDL. [15] Statins reduce the cholesterol by inhibiting hydroxylmethylglutaryl CoA reductase, thereby reducing coronary heart disease end points in type 2 diabetes. [16] Omega-3-fatty acids (eicosapentanoic and docosahexanoic acid) reduce plasma triglycerides by 20% when used in combination with other triglyceride-lowering therapies. [17] Antioxidant therapies (Selenium, β carotene, vitamin C, α-tocopherol) have been used in the reduction of recurrent pancreatitis episodes that have remained markedly hypertriglyceridemic after medical therapy, by virtue of their protection from free radical-induced acinar damage. [18] Our patient had been prescribed a combination of fenofibrate, atorvastatin, omega-3 fatty acids, and antioxidants. Other options include niacin, bile acid binding resins, and glitazar drugs. Novel modalities include the use of medium chain triglycerides (they do not require chylomicron formation for absorption), plasmapheresis, [13] insulin and heparin, [19] and lipoprotein lipase gene therapy. [20]
| Conclusion | | |
Hypertriglyceridemia is a common clinical problem, and if markedly elevated, can lead to pancreatitis. General and specific therapies are available to reduce triglycerides during the acute phases of pancreatitis. Nutrition, pharmacological therapy, and avoiding aggravating factors are essential for preventing further attacks.
| Acknowledgements | | |
All the authors would extend their heartfelt thanks to Dr. Jagadeesh Tangudu, M Tech, MS, PhD and Sowmya Jammula, M Tech for their immense and selfless contribution towards manuscript preparation, language editing and final approval of text.
| References | | |
| 1. | Toskes PP. Hyperlipidemic pancreatitis. Gastroenterol Clin North Am 1990;19:783-91. 
[PUBMED] |
| 2. | Dominguez-Munoz JE, Malfertheiner P, Ditschuneit HH, Blanco-Chavez J, Uhl W, Buchler M, et al. Hyperlipidemia in acute pancreatitis. Relationship with etiology, onset and severity of the disease. Int J Pancreatol 1991;10:261-7.
|
| 3. | Seales CE, Ooi TC. Underrecognition of chylomicronemia as a cause of acute pancreatitis. CMAJ 1992;147:1806-8.
|
| 4. | Lithell H, Vessby B, Walldius G, Carlson LA. Hypertriglyceridemia-acute pancreatitis-ischemic heart disease. A case study in a pair of monozygotic twins. Acta Med Scand 1987;221:311-6.
[PUBMED] |
| 5. | Fortson MR, Freedman SN, Webster PD 3 rd . Clinical assessment of hyperlipidemic pancreatitis. Am J Gastroenterol 1995;90:2134-9.
|
| 6. | Monga A, Arora A, Makkar RP, Gupta AK. Hypertriglyceridemia- induced- acute pancreatitis- treatment with hepatin and insulin. Indian J Gastroenterol 2003;22:102-3.
[PUBMED] |
| 7. | Yeh JH, Chen JH, Chiu HC. Plasmapheresis for hyperlipidemic pancreatitis. J Clin Apheresis 2003;18:181-5.
[PUBMED] [FULLTEXT] |
| 8. | Yadav D, Pitchumoni CS. Issues in hyperlipidemic pancreatitis. J Clin Gastroenterol 2003;36:54-62.
[PUBMED] [FULLTEXT] |
| 9. | Lemieux I, Pascot A, Couillard C, Lamarche B, Tchernof A, Alméras N, et al. Hypertriglyceridemic waist: A marker of the atherogenic metabolic triad (hyperinsulinemia; hyperapolipoprotein B; small dense LDL) in men? Circulation 2000;102:179-84.
|
| 10. | Hegele RA. Monogenic dyslipidemias: Window on determinants of plasma lipoprotein metabolism. Am J Hum Genet 2001;69:1161-77.
[PUBMED] [FULLTEXT] |
| 11. | Kimura W, Mossner J. Role of hypertriglyceridemia in the pathogenesis of experimental acute pancretitis in rats. Int J Pancreatol 1996;20:177-84.
|
| 12. | Expert panel on detection, evaluation and treatment of high blood cholesterol in adults. Executive summary of the third report of the National Cholesterol Education Programme (NCEP) Expert panel on detection, evaluation and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001;285:2486-97.
|
| 13. | Barter PJ, Rye KA. Cardioprotective properties of fibrates: Which fibrate, which patients, what mechanism? Circulation 2006;113:1553-5.
[PUBMED] [FULLTEXT] |
| 14. | Rubins HB, Robins SJ, Collins D, Nelson DB, Elam MB, Schaefer EJ, et al. Diabetes, plasma insulin and cardiovascular disease: Subgroup analysis from the Department of Veterans Affairs high density lipoprotein intervention trial (VA-HIT). Arch Intern Med 2002;162:2597-604.
[PUBMED] [FULLTEXT] |
| 15. | Frick MH, Elo O, Haapa K, Heinonen OP, Heinsalmi P, Helo P, et al. Helsinki Heart Study: Primary-prevention trial with gemfibrozil in middle aged men with dyslipidemia. Safety of treatment, changes in risk factors and incidence of coronary heart disease. N Engl J Med 1987;317:1237-45.
[PUBMED] [FULLTEXT] |
| 16. | Gami AS, Montori VM, Erwin PJ, Khan MA, Smith SA; Evidence in Diabetes Enquiry System (EVIDENS) Research Group. Systematic review of lipid lowering for primary prevention of coronary heart disease in diabetes. BMJ 2003;326:528-9.
[PUBMED] [FULLTEXT] |
| 17. | Hooper L, Thompson RL, Harrison RA, Summerbell CD, Ness AR, Moore HJ, et al. Risks and benefits of omega 3 fats for mortality, cardiovascular disease and cancer: Systematic review. BMJ 2006;332:752-60.
[PUBMED] [FULLTEXT] |
| 18. | Topol EJ. Intensive statin therapy-A sea change in cardiovascular prevention. N Engl J Med 2004;350:1562-4.
[PUBMED] [FULLTEXT] |
| 19. | Tenenbaum A, Motro M, Fisman EZ, Tanne D, Boyko V, Behar S. Benzafibrate for the secondary prevention of myocardial infarction in patients with metabolic syndrome. Arch Intern Med 2005;165:1154-60.
[PUBMED] [FULLTEXT] |
| 20. | Rip J, Nierman MC, Sierts JA, Petersen W, Van den Oever K, Van Raalte D, et al. Gene therapy for lipoprotein lipase deficiency: Working towards clinical application. Hum Gene Ther 2005;16:1276-86.
[PUBMED] [FULLTEXT] |
[Figure 1]
[Table 1]
| This article has been cited by | | 1 |
Effects of Huatan Jiangzhuo decoction on diet-induced hyperlipidemia and gene expressions in rats |
|
| Qi REN,Xiao-Qi LIU,Xiao-Wen ZHOU,Xuan ZHOU,Ge FANG,Bin WANG,Yan-Ping WANG,Dan-Hong PENG,Xian-Tao LI | | Chinese Journal of Natural Medicines. 2021; 19(2): 100 | | [Pubmed] | [DOI] | | | 2 |
Urinary copper, Systemic Inflammation, and Blood Lipid Profiles: Wuhan-Zhuhai Cohort study |
|
| Jixuan Ma,Yujia Xie,Yun Zhou,Dongming Wang,Limin Cao,Min Zhou,Xing Wang,Bin Wang,Weihong Chen | | Environmental Pollution. 2020; : 115647 | | [Pubmed] | [DOI] | | | 3 |
Relationships between Metabolic Comorbidities and Occurrence, Severity, and Outcomes in Patients with Acute Pancreatitis: A Narrative Review |
|
| Xu Li,Xiaolin Guo,Huifan Ji,Junqi Niu,Pujun Gao | | BioMed Research International. 2019; 2019: 1 | | [Pubmed] | [DOI] | | | 4 |
Severe hypertriglyceridemia. Clinical characteristics and therapeutic management |
|
| Walter Masson,Emiliano Rossi,Daniel Siniawski,Juan Damonte,Ana Halsband,Ramiro Barolo,Miguel Scaramal | | Clínica e Investigación en Arteriosclerosis (English Edition). 2018; | | [Pubmed] | [DOI] | | | 5 |
Hipertrigliceridemia grave. Características clínicas y manejo terapéutico |
|
| Walter Masson,Emiliano Rossi,Daniel Siniawski,Juan Damonte,Ana Halsband,Ramiro Barolo,Miguel Scaramal | | Clínica e Investigación en Arteriosclerosis. 2018; | | [Pubmed] | [DOI] | | | 6 |
A lipemic blood sample in the paediatric critical care unit |
|
| Brianna McKelvie,Robert Stein | | Paediatrics & Child Health. 2018; | | [Pubmed] | [DOI] | | | 7 |
Management of Hypertriglyceridemia Induced Acute Pancreatitis |
|
| Rajat Garg,Tarun Rustagi | | BioMed Research International. 2018; 2018: 1 | | [Pubmed] | [DOI] | | | 8 |
Hypertriglyceridemia-induced pancreatitis: updated review of current treatment and preventive strategies |
|
| Prashanth Rawla,Tagore Sunkara,Krishna Chaitanya Thandra,Vinaya Gaduputi | | Clinical Journal of Gastroenterology. 2018; | | [Pubmed] | [DOI] | | | 9 |
Biosensing methods for determination of triglycerides: A review |
|
| C.S. Pundir,Vinay Narwal | | Biosensors and Bioelectronics. 2018; 100: 214 | | [Pubmed] | [DOI] | | | 10 |
Hypertriglyceridemic acute pancreatitis in emergency department: Typical clinical features and genetic variants |
|
| Wan Jun Chen,Xiao Fan Sun,Rui Xue Zhang,Min Jie Xu,Tong Hai Dou,Xiao Bin Zhang,Min Zhong,Wei Qiang Yang,Li Liu,Xiao Ye Lu,Chang Qing Zhu | | Journal of Digestive Diseases. 2017; 18(6): 359 | | [Pubmed] | [DOI] | | | 11 |
Heparin and insulin in the management of hypertriglyceridemia-associated pancreatitis: case series and literature review |
|
| Mohammad Shafi Kuchay,Khalid J. Farooqui,Tarannum Bano,Manoj Khandelwal,Harmandeep Gill,Ambrish Mithal | | Archives of Endocrinology and Metabolism. 2017; 61(2): 198 | | [Pubmed] | [DOI] | | | 12 |
An improved amperometric triglyceride biosensor based on co-immobilization of nanoparticles of lipase, glycerol kinase and glycerol 3-phosphate oxidase onto pencil graphite electrode |
|
| Vinay Narwal,C.S. Pundir | | Enzyme and Microbial Technology. 2017; | | [Pubmed] | [DOI] | | | 13 |
ANALYSIS OF SERUM LIPID PROFILE IN PATIENTS WITH PANCREATITIS |
|
| Yuvraj Kumar Churendra,Bhupati Bhusan Das,Sushanta Kumar Das,Niranjan Sahoo,Mahammad Asfak Ahmed,Charan Panda | | Journal of Evolution of Medical and Dental Sciences. 2016; 5(43): 2706 | | [Pubmed] | [DOI] | | | 14 |
The clinical relevance of omega-3 fatty acids in the management of hypertriglyceridemia |
|
| James Backes,Deborah Anzalone,Daniel Hilleman,Julia Catini | | Lipids in Health and Disease. 2016; 15(1) | | [Pubmed] | [DOI] | | | 15 |
Hypertriglyceridemia: the importance of identifying patients at risk |
|
| Pamela A. Kushner,Michael E. Cobble | | Postgraduate Medicine. 2016; 128(8): 848 | | [Pubmed] | [DOI] | | | 16 |
Other Risks/Possible Benefits of Obesity |
|
| Lisa P. Weeth | | Veterinary Clinics of North America: Small Animal Practice. 2016; | | [Pubmed] | [DOI] | | | 17 |
Acute pancreatitis associated with severe hypertriglyceridaemia; A retrospective cohort study |
|
| Annika Charlesworth,Adrian Steger,Martin A. Crook | | International Journal of Surgery. 2015; 23: 23 | | [Pubmed] | [DOI] | | | 18 |
Acute management of hyperlipaemic pancreatitis: a successful reduction in triglyceride levels with simultaneous insulin infusion and plasma exchange |
|
| A Korb,PH Sonnekus,JD Botha | | Journal of Endocrinology, Metabolism and Diabetes of South Africa. 2015; : 1 | | [Pubmed] | [DOI] | | | 19 |
Hypertriglyceridemic Pancreatitis Caused by the Oral Contraceptive Agent Estrostep |
|
| Mary Abraham,Jennifer Mitchell,Debra Simsovits,James Gasperino | | Journal of Intensive Care Medicine. 2015; 30(5): 303 | | [Pubmed] | [DOI] | | | 20 |
Etiology, clinical features and management of acute recurrent pancreatitis |
|
| Yi Yun Deng,Rui Wang,Hao Wu,Cheng Wei Tang,Xin Zu Chen | | Journal of Digestive Diseases. 2014; 15(10): 570 | | [Pubmed] | [DOI] | | | 21 |
Extended Exenatide Administration Enhances Lipid Metabolism and Exacerbates Pancreatic Injury in Mice on a High Fat, High Carbohydrate Diet |
|
| Rodney Rouse,Leshuai Zhang,Katherine Shea,Hongfei Zhou,Lin Xu,Sharron Stewart,Barry Rosenzweig,Jun Zhang,Francisco X. Real | | PLoS ONE. 2014; 9(10): e109477 | | [Pubmed] | [DOI] | | | 22 |
Protective effects of Portulaca oleracea against cerulein-induced acute pancreatitis |
|
| Tae-Sin Gwak,Dong-Goo Kim,Ju-Young Kim,Gi-Sang Bae,Sun-Bok Choi,Il-Joo Jo,Joon-Yeon Shin,Sung-Kon Lee,Myoung-Jin Kim,Min-Jun Kim,Ho-Joon Song,Sung-Joo Park | | The Korea Journal of Herbology. 2014; 29(3): 11 | | [Pubmed] | [DOI] | |
|
 |
|
|
|
